Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer

Copur S., Sag A. A. , AFŞAR B. , Rossignol P., Covic A., Kanbay M.

INTERNATIONAL UROLOGY AND NEPHROLOGY, 2020 (SCI İndekslerine Giren Dergi) identifier identifier


Chronic kidney disease is prevalent, affecting more than one in ten adults. In this population, metabolic acidosis is considered a key underlying pathophysiological feature, tying together bone mineral disorders, sarcopenia, insulin resistance, vascular calcification, pro-inflammatory and pro-thrombotic states. This review aims to address the paucity of literature on alkalinizing agents, a promising treatment option that has known adverse effects.